Table 2.

Baseline characteristics of study participants [n is variable depending on availability of data]

Variable	Frequency	Proportion (%)
ART Usage (n = 461)
ART-experienced ART-naïve	431 30	93.5 6.5
WHO Clinical Staging (n = 453)
1 2 3	382 64 7	84.3 14.1 1.5
VL (copies/ml) (n = 430)
< 50 50 − 999 ≥ 1000	397 27 6	92.3 6.3 1.4
CD4 (cells/mm3)(n = 403)
< 200 200 − 350 351 − 500 > 500	28 47 90 238	6.9 11.7 22.3 59.1
Previous ART Regimen (n = 431)
Tenofovir/Emtricitabine/Efavirenz Other	411 20	95.4 4.6